Delving into the Latest Updates on Iobenguane I-123 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Diagnostic radiopharmaceuticals

Synonyms

123I-Iobenguane, 3-Iodobenzylguanidine (123I), 3-Iodobenzylguanidine (123I) Injection

+ [8]

Target-

Mechanism

SPECT(Single-photon emission-computed tomography enhancers)

Therapeutic Areas

NeoplasmsCardiovascular DiseasesOther Diseases

Active Indication

Heart FailureNeuroblastomaPheochromocytoma+ [1]

Inactive Indication

Coronary Artery Disease

Originator Organization

GE Healthcare, Inc.

Active Organization

PDRadiopharma, Inc.GE Healthcare, Inc.

Inactive Organization

GE Healthcare Holdings, Inc.

Drug Highest PhaseApproved

First Approval Date

JP (02 Oct 1992),

Diagnostic agents

RegulationOrphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC8H10IN3

InChIKeyPDWUPXJEEYOOTR-IUAIQHPESA-N

CAS Registry76924-93-1

View All Structures (2)

Prospective study of I-131 3-iodobenzylguanidine radiotherapy for high-risk neuroblastoma; in accordance with the Japanese Advanced Medical Care B program for the anticancer drug with high medical needs. - Prospective study of I-131 3-iodobenzylguanidine radiotherapy for high-risk neuroblastoma; in accordance with the Japanese Advanced Medical Care B program for the anticancer drug with high medical needs.

Start Date01 Jul 2017

Sponsor / Collaborator

Kanazawa University

100 Clinical Results associated with Iobenguane I-123

Login to view more data

100 Translational Medicine associated with Iobenguane I-123

Login to view more data

100 Patents (Medical) associated with Iobenguane I-123

Login to view more data

256

Literatures (Medical) associated with Iobenguane I-123

01 Oct 2024·Annals of Nuclear Medicine

Sympathetic 123I-metaiodobenzylguanidine index for Lewy body disease: probability-based diagnosis and identifying patients exempt from late imaging

Article

Author: Komatsu, Junji ; Kinuya, Seigo ; Ono, Kenjiro ; Wakabayashi, Hiroshi ; Nakajima, Kenichi ; Matsumura, Takeshi

AbstractObjectiveWe aimed to establish a practical diagnostic index for Lewy body diseases (LBD), such as Parkinson’s disease and dementia, with Lewy bodies in outpatient settings and criteria for exempting patients from late imaging.MethodsWe acquired early and late 123I-metaiodobenzylguanidine (MIBG) images from 108 consecutive patients with suspected LBD and standardized heart-to-mediastinum (H/M) ratios for collimator conditions. Exclusions included young-onset Parkinson’s disease (age < 50 years) and genetic transthyretin-type amyloidosis. We developed logistic models incorporating H/M ratios with or without age (n = 92). The sympathetic MIBG index for LBD (SMILe index), categorized LBD likelihood from 0 (lowest) to 1 (highest). Diagnostic accuracy was assessed as the area under the receiver operating characteristic (ROC) curve (AUC). The characteristics of the new index were compared with H/M ratios. The need for late imaging was explored using the SMILe index.ResultsEarly or late SMILe indexes using a single H/M ratio variable discriminated LBD from non-LBD. The AUC values for early and late SMILe indexes were 0.880 and 0.894 (p < 0.0001 for both), identical to those for early and late H/M ratios. The sensitivity and the specificity of early SMILe indexes with a 0.5 threshold were 76% and 90%, achieving accuracy of accuracy 86%. Similarly, the late SMILe index demonstrated a sensitivity of 76% and specificity of 87%, with an accuracy of 84%. Early SMILe indexes < 0.3 or > 0.7 (representing 84% patients) indicated a diagnosis without a late MIBG study.ConclusionThe 123I-MIBG-derived SMILe indexes provide likelihood of LBD, and those with a 50% threshold demonstrated optimal diagnostic accuracy for LBD. The index values of either < 0.3 or > 0.7 accurately selected patients who do not need late imaging.

01 Sep 2024·Journal of Nuclear Cardiology

Quantitative assessment of cardiac 123iodo-metaiodobenzylguanidine SPECT/CT in patients with arrhythmogenic right ventricular cardiomyopathy: Novel insight in disease monitoring

Article

Author: Clauß, Sebastian ; Hagen, Johannes M ; Fischer, Maximilian ; Bartenstein, Peter ; Böning, Guido ; Brendel, Matthias ; Zacherl, Mathias J ; Todica, Andrei ; Kääb, Stefan

BACKGROUNDThe heart-to-mediastinum ratio (H/M-Ratio) of ¹²³iodo-metaiodobenzylguanidine (¹²³I-MIBG) represents state-of-the-art assessment for sympathetic dysfunction in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). This study aims to evaluate quantitative reconstruction of ¹²³I-MIBG uptake and to demonstrate its correlation with echocardiographic parameters.METHODSCardiac innervation was assessed in 23 patients diagnosed with definite ARVC or borderline ARVC and 12 patients with other cardiac disease presenting arrhythmia, using quantitative ¹²³I-MIBG Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) imaging. Tracer uptake was evaluated in the left (LV) and right ventricle (RV) based on a CT scan after quantitative image reconstruction. The relationship between tracer uptake and echocardiographic parameter data was examined.RESULTSAbsolute quantification of ¹²³I-MIBG uptake in the LV and RV is feasible and correlates accurately with the gold standard H/M Ratio. When comparing sensitivity and specificity, the area under the curve (AUC) favors standardized uptake value (SUV) of the RV over the right-ventricle-to-mediastinum-ratio (RV/M-Ratio) for diagnosing ARVC. A reduced RV-SUV in patients with definite ARVC is associated with reduced RV function. RV polar maps revealed globally reduced ¹²³I-MIBG uptake without segment-specific reduction in the RV.CONCLUSIONSQuantitative ¹²³I-MIBG SPECT in ARCV patients offers robust potential for clinical reporting and demonstrates a significant correlation with RV function. Segmental RV analysis needs to be evaluated in larger samples. In summary, cardiac ¹²³I-MIBG imaging using SUV could facilitate image-guided therapy in patients diagnosed with ARVC.

25 Jun 2024·Journal of Alzheimer's Disease

Diagnostic Sensitivity and Symptomatic Relevance of Dopamine Transporter Imaging and Myocardial Sympathetic Scintigraphy in Patients with Dementia with Lewy Bodies

Article

Author: Yamagishi, Kosuke ; Tang, Zhihui ; Ishikawa, Ai ; Izumi, Michiko ; Kitayama, Yoshihisa ; Uno, Takashi ; Kashiwado, Kouichi ; Kuwabara, Satoshi ; Iimori, Takashi ; Mukai, Hiroki ; Hirano, Shigeki ; Tamura, Mitsuyoshi ; Horikoshi, Takuro ; Yokota, Hajime ; Koizumi, Yume

Background: Dementia with Lewy bodies (DLB) presents with various symptoms, posing challenges for early diagnosis challenging. Dopamine transporter (123I-FP-CIT) single-photon emission tomography (SPECT) and 123I-meta-iodobenzylguanidine (123I-MIBG) imaging are crucial diagnostic biomarkers. Hypothesis about body- and brain-first subtypes of DLB indicate that some DLB may show normal 123I-FP-CIT or 123I-MIBG results; but the characteristic expression of these two subtypes remains unclear. Objective: This study aimed to evaluate the diagnostic sensitivity of 123I-FP-CIT and 123I-MIBG imaging alone, combined in patients with DLB and explore symptoms associated with the abnormal imaging results. Methods: Demographic data, clinical status, and imaging results were retrospectively collected from patients diagnosed with possible DLB. Both images were quantified using semi-automated software, and the sensitivity of each imaging modality and their combination was calculated. Demographic data, cognition, and motor and non-motor symptoms were compared among the subgroups based on the imaging results. Symptoms related to each imaging abnormality were examined using binomial logistic regression analyses. Results: Among 114 patients with DLB, 80 underwent 123I-FP-CIT SPECT (sensitivity: 80.3%), 83 underwent 123I-MIBG imaging (68.2%), and 66 both (sensitivity of either abnormal result: 93.9%). Visual hallucinations differed among the four subgroups based on imaging results. Additionally, nocturia and orthostatic hypotension differed between abnormal and normal 123I-MIBG images. Conclusions: Overall, 123I-FP-CIT SPECT was slightly higher sensitivity than 123I-MIBG imaging, with combined imaging increasing diagnostic sensitivity. Normal results of a single imaging test may not refute DLB. Autonomic symptoms may lead to abnormal 123I-MIBG scintigraphy findings indicating body-first subtype of patients with DLB.

100 Deals associated with Iobenguane I-123

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V09	DB09546

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	US	GE Healthcare, Inc.	20 Mar 2013
Neuroblastoma	US	GE Healthcare, Inc.	19 Sep 2008
Pheochromocytoma	US	GE Healthcare, Inc.	19 Sep 2008
Diagnostic agents	JP	PDRadiopharma, Inc.	02 Oct 1992

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart Failure	Phase 2	CA	GE Healthcare Holdings, Inc.	01 Dec 2013
Coronary Artery Disease	Phase 1	CA	GE Healthcare Holdings, Inc.	01 Dec 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2023	Not Applicable	Pheochromocytoma	-	123I-meta-iodobenzylguanidine	lxenlzldnf(vllzybkkoh) = At each time point, the trends of the biodistribution of ¹²³I-MIBG and ²¹¹At-MABG were almost similar in pheochromocytoma xenograft mice dyorlwaowv (uojkmevcmx )	-	28 Aug 2023
				211At-astato-benzylguanidine
SNMMI2020	Not Applicable	-	-	123I-MIBG	kimwfvlrxv(odsjtybyrj) = kdbcjburpe atbnlgxcsg (crgoohnhli, 8.86) View more	-	15 May 2020
				211At-MABG	kimwfvlrxv(odsjtybyrj) = ptuvfvcota atbnlgxcsg (crgoohnhli, 4.79) View more
NCT02656329 (ADMIRE-ICD, CTgov)	Phase 3	Heart failure NYHA class III	395	Thyroid blocking+Iobenguane I -123 Injection (AdreView™)	(vyvgkhlpfm) = ichapmarka hczrzagmll (ifnisriadw, vxnueorcpt - djyoobnzxs) View more	-	22 May 2019
				Implantable Cardioverter Defibrillator+Iobenguane I -123 Injection (Standard of Care)	(vyvgkhlpfm) = tkwsuoctcf hczrzagmll (ifnisriadw, vowvryxkeb - wivvsizyss) View more
SNMMI2017	Not Applicable	High Risk Neuroblastoma 123I-MIBG	76	123I-MIBG (New detailed semi-quantitative scoring system)	jugbnexlnz(ojqzrifvcq) = tlwyjzseqi osxvyttrnu (esrlskmekt )	Positive	24 May 2017
ESC2016	Not Applicable	ST Elevation Myocardial Infarction	94	123I-MIBG SPECT	htybnehawg(qpeicryrnt) = jfhdwoawgv yisolwmabi (ejtczttdjf )	-	30 Aug 2016
AAIC2016	Not Applicable	Lewy Body Disease	-	123I-2β-Carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-CIT) dopamine transporter (DAT) SPECT	(gweeghzrvu) = wfschiztlx zjsojkkpnr (yiruusiabn )	-	01 Jul 2016
				123I-metaiodobenzylguanidine (MIBG) myocardial SPECT	(gweeghzrvu) = tkmsjzhfka zjsojkkpnr (yiruusiabn )
SNMMI2015	Not Applicable	Thyroid Diseases	-	123I-MIBG (CHF patients)	vyfierrois(xzapvggrth) = inrzlnncce bijqhcbvfc (wvgficulwx, 7.2) View more	-	15 May 2015
				123I-MIBG (PD-MD patients)	vyfierrois(xzapvggrth) = dcmzyvqzyu bijqhcbvfc (wvgficulwx, 8.1)
SNMMI2015	Not Applicable	-	-	123I-mIBG	aohlcrqgif(lbeskdckfh) = oovjhrtlco pwjyrozzef (hevorjuesp, 4.3)	-	15 May 2015
SNMMI2014	Not Applicable	Arrhythmias, Cardiac	-	123I-mIBG SPECT	nuhwhgdaun(prxaislivr) = ffzolgfheu ttayttthsj (skmcbvqceo )	-	05 Nov 2014
				123I-mIBG (Contrast enhanced CT (cCT) or Cardiac MRI (CMR))	nuhwhgdaun(prxaislivr) = koqqkboxxq ttayttthsj (skmcbvqceo )
Pubmed \| Parkinsonism Relat Disord	Not Applicable	Parkinsonian Disorders \| Parkinson Disease (123)I-meta-iodobenzylguanidine ((123)I-MIBG)	845	123I-MIBG	(qhcwiybskq) = ceunbfjgkk whzdzvyasz (yjpneftlkq ) View more	-	01 Jun 2012
				123I-MIBG	(qhcwiybskq) = ebrxklkvak whzdzvyasz (yjpneftlkq ) View more